Program
Nivolumab
Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.
Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 12410 open or running | phase 4since Nov 2, 2015 | Feb 27, 2007 | Feb 5, 2027phase 2 · NCT06946797 |
| Ono Pharmaceuticalits history only | 144 open or running | phase 3since Oct 9, 2014 | Jan 26, 2009 | Dec 31, 2027phase 2 · NCT04566380 |
| Pfizerits history only | 20 open or running | phase 2since Oct 7, 2015 | Oct 7, 2015 | none ahead |
| Ella Therapeuticsits history only | 10 open or running | phase 2since Aug 13, 2020 | Aug 13, 2020 | none ahead |
| ExcellaBioits history only | 10 open or running | phase 2since Oct 20, 2017 | Oct 20, 2017 | none ahead |
| Nilogen Oncosystemsits history only | 10 open or running | early phase 1since Dec 3, 2017 | Dec 3, 2017 | none ahead |
| Rampart Healthits history only | 10 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| USWM CTits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 14, 2016.
- Mar 16, 2020Phase 1 study in NeoplasmsNCT04311710 · 21 enrolled · United States, Italy, New Zealand
- Apr 7, 2020Phase 3 study in Liver NeoplasmsNCT04340193 · 26 enrolled · United States, Australia, Austria and more
- Jul 30, 2020Phase 2 study in MelanomaNCT04495010 · United States, Australia, Austria and more
- Aug 13, 2020Phase 4 study in Kidney NeoplasmsNCT04513522 · 101 enrolled · India
- Sep 24, 2020Phase 2 study in Carcinoma, HepatocellularNCT04567615 · 266 enrolled · Argentina, Brazil, Chile and more
- Nov 18, 2021Phase 2 study in Mesothelioma, MalignantNCT05136677 · 102 enrolled · China
- Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
- Aug 9, 2022Phase 2 study in MelanomaNCT05496192 · Germany, Spain
- Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
- Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
- Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
- Apr 25, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06946797 · 76 enrolled · United States, Brazil, Chile and more
- Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06946797
- May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
- Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
- Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 124 Bristol-Myers Squibb leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459543Melanoma · India | 4 | Not yet recruiting | May 26, 2029 | 40 |
| NCT06946797Carcinoma, Non-Small-Cell Lung · United States, Brazil, Chile and more | 2 | Active, not recruiting | Feb 5, 2027 | 76 |
| NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jul 30, 2030 | 1,000 |
| NCT06101134Melanoma · United States, Chile, Greece and more | 2 | Active, not recruiting | Apr 10, 2025 | 100 |
| NCT05625399Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 4, 2025 | 579 |
| NCT05498480Advanced Solid Tumors · China | 1 | Completed | Jan 18, 2024 | 6 |
| NCT05496192Melanoma · Germany, Spain | 2 | Withdrawn | Jun 24, 2024 | 0 |
| NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more | 2 | Terminated | Dec 3, 2025 | 5 |
| NCT05136677Mesothelioma, Malignant · China | 2 | Completed | Nov 12, 2025 | 102 |
| NCT04567615Carcinoma, Hepatocellular · Argentina, Brazil, Chile and more | 2 | Completed | Aug 31, 2023 | 266 |
| NCT04513522Kidney Neoplasms · India | 4 | Completed | Jan 4, 2024 | 101 |
| NCT04495010Melanoma · United States, Australia, Austria and more | 2 | Withdrawn | Feb 28, 2024 | 0 |
| NCT04340193Liver Neoplasms · United States, Australia, Austria and more | 3 | Completed | Dec 12, 2023 | 26 |
| NCT04311710Neoplasms · United States, Italy, New Zealand | 1 | Terminated | Jan 14, 2021 | 21 |
| NCT04209114Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jun 7, 2023 | 114 |
| NCT04151563Carcinoma · United States, Argentina, Belgium and more | 2 | Withdrawn | Dec 17, 2023 | 0 |
| NCT04149574Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Oct 31, 2023 | 13 |
| NCT04109066Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jan 16, 2023 | 521 |
| NCT04100018Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jun 1, 2023 | 1,030 |
| NCT04099251Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Jun 28, 2022 | 790 |
| NCT04088500Carcinoma, Renal Cell · United States, Canada | 2 | Terminated | Nov 15, 2021 | 5 |
| NCT04075604Breast Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Jul 27, 2021 | 23 |
| NCT04039607Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Jul 9, 2026 | 732 |
| NCT04026412Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Mar 22, 2024 | 925 |
| NCT04025879Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 26, 2023 | 461 |
| NCT04008030Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 28, 2024 | 839 |
| NCT03980314Melanoma · United States, Argentina, Australia and more | 1 | Completed | Mar 4, 2021 | 261 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Aug 25, 2029 | 1,500 |
| NCT03770299Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Mar 14, 2023 | 0 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Feb 27, 2022 | 0 |
| NCT03668119Pan Tumor · United States, Argentina, Australia and more | 2 | Completed | May 3, 2022 | 212 |
| NCT03661320Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Feb 16, 2026 | 855 |
| NCT03656718Neoplasms by Site · United States, Argentina, Brazil and more | 2 | Completed | Sep 7, 2022 | 139 |
| NCT03519256Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Terminated | Aug 22, 2022 | 142 |
| NCT03444766Carcinoma, Non-Small-Cell Lung · India | 4 | Completed | Jul 17, 2019 | 100 |
| NCT03414983Colorectal Neoplasms · United States, Canada, Japan and more | 3 | Completed | Feb 1, 2021 | 196 |
| NCT03383458Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 27, 2026 | 545 |
| NCT03377361Colorectal Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Nov 4, 2024 | 325 |
| NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more | 3 | Completed | Oct 14, 2019 | 74 |
| NCT03338790Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Jan 13, 2021 | 292 |
| NCT03215706Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Aug 16, 2019 | 719 |
| NCT03195491Lung Neoplasms · China, Thailand | 3 | Completed | Jun 8, 2021 | 400 |
| NCT03195478Solid Tumor · China | 2 | Completed | Jan 5, 2024 | 37 |
| NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more | 3 | Completed | Jan 18, 2021 | 970 |
| NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Feb 12, 2020 | 701 |
| NCT03138512Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Sep 28, 2023 | 1,641 |
| NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico | 3 | Terminated | Feb 22, 2021 | 23 |
| NCT03130959Various Advanced Cancer · United States, Australia, Brazil and more | 2 | Completed | Mar 10, 2020 | 166 |
| NCT03098550Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Jul 6, 2020 | 105 |
| NCT03090737Carcinoma, Non-Small-Cell Lung · United States, Canada, Japan and more | 2 | Completed | Feb 16, 2021 | 129 |
| NCT03048136Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more | 3 | Withdrawn | Sep 29, 2019 | 0 |
| NCT03036098Urothelial Cancer · United States, Argentina, Australia and more | 3 | Completed | Aug 30, 2024 | 1,314 |
| NCT03029780Carcinoma, Renal Cell · United States, Australia, Chile | 2 | Completed | Nov 27, 2017 | 104 |
| NCT03001882Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 2 | Completed | Feb 17, 2022 | 230 |
| NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Completed | Sep 8, 2021 | 505 |
| NCT02982954Carcinoma, Renal Cell · United States | 4 | Completed | May 11, 2020 | 211 |
| NCT02985957Prostatic Neoplasms · United States, Australia, Austria and more | 2 | Completed | Apr 5, 2022 | 351 |
| NCT02960854Sepsis · United States | 1 | Completed | Jan 5, 2018 | 38 |
| NCT02927769Hodgkin Disease · United States, Canada, Czechia and more | 2 | Completed | May 28, 2024 | 72 |
| NCT02905266Melanoma · Australia, France, Italy and more | 3 | Completed | Oct 23, 2017 | 106 |
How it is read
Names in the registry
- “Nivolumab”, 115 entries
- “nivolumab”, 18 entries
- “ONO-4538”, 13 entries
- “BMS-936558 (MDX-1106)”, 5 entries
- “Nivolumab + Relatlimab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 36 studies
- Melanoma, 21 studies
- Carcinoma, Renal Cell, 11 studies
- Carcinoma, Hepatocellular, 6 studies
- Colorectal Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.